CA2669102A1 — Tetralin analogs having sphingosine 1-phosphate agonist activity
Assigned to UVA Licensing and Ventures Group · Expires 2008-05-29 · 18y expired
What this patent protects
Tetralin analogs that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at SlP receptors.
USPTO Abstract
Tetralin analogs that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at SlP receptors.
Drugs covered by this patent
- Mayzent (SIPONIMOD) · Novartis
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.